X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Aligned Pathway

    UK Grants Pharma Firms Early Access to Aligned Pathway

    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Aligned Pathway

    UK Grants Pharma Firms Early Access to Aligned Pathway

    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Research & Development

Weight-Loss Surgery, Prescriptions More Satisfying for Obese Patients

Yuvraj_pawp by Yuvraj_pawp
9th July 2014
in Research & Development

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Obese patients who underwent surgery or took medications to lose weight were more satisfied with their results than those who made lifestyle changes.

 

Nearly 60% of obese patients are not taking any action to lose weight, according to the results of a recent analysis of the 2012 National Health and Wellness Survey conducted by Eisai Inc and Kantar Health. The study, presented on June 21, 2014, at the 16th International Congress of Endocrinology and the Endocrine Society’s 96th Annual Meeting and Expo in Chicago, also found that among obese individuals who did attempt to lose weight, those who underwent surgery or took prescription medications were more satisfied with their weight loss than those who made lifestyle modifications.

 

Researchers of the study analyzed the weight-loss satisfaction of 22,927 obese adults and 19,121 obese adults who had at least 1 related comorbidity including type 2 diabetes, hypertension, or dyslipidemia. Patients were categorized as having undergone a weight-loss surgery or using a prescription for weight loss or using self-modifications such as diet, exercise, weight management programs, and over-the-counter medications and supplements to lose weight. Overall satisfaction with current weight-loss methods was analyzed on a scale from 1 (extremely dissatisfied) to 7 (extremely satisfied).

 

Of the 22,927 obese patients included in the analysis, 58.4% were not attempting to lose weight. This result suggests “the need for more education on obesity awareness/prevention,” the authors of the study noted.

 

Only 2.3% of patients used surgery or prescription medications to lose weight, while 39.3% were in the self-modification group. The results indicated that patients who used surgery or medications were significantly more satisfied with their weight-loss methods than those who made lifestyle changes. Among obese patients who had weight-loss surgery or took medications, 39.3% reported being extremely or very satisfied, compared with just 20.2% of modification patients. Similar results were observed among obese and overweight patients with comorbidities; 44.4% of patients in the surgery and prescription group were extremely or very satisfied, compared with 19.7% among those in the modification group. Treatment satisfaction did not significantly vary between patients using a prescription and those who had surgery.

 

“This finding may mean that diet and exercise alone just don’t work for a lot of people,” said lead investigator Z. Jason Wang, PhD, director of Health Economics and Outcomes at Eisai in Woodcliff Lake, NJ, in a press release. “Drug treatment and bariatric surgical procedures should be considered an integral part of weight management for eligible patients to achieve better treatment satisfaction, which may in turn help patients achieve and maintain better long-term weight loss.”

Previous Post

Rotavirus Vaccination Decreases Diarrhea Hospitalizations Among Kids

Next Post

Strativa Pharmaceuticals Announces FDA Approval of Nascobal® (Cyanocobalamin, USP) Nasal Spray Single-Use Device

Related Posts

Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
wearable drug delivery devices
Insights

Wearable Drug Delivery Devices for On-Demand Care

27th September 2025
biologic drug formulation stability
Drug Development

Breakthroughs in Biologic Drug Formulation Stability

27th September 2025
high volume injectable formulations
Insights

Overcoming Challenges in High-Volume Injectable Formulations

27th September 2025
Insights

Green Chemistry in Sustainable API Manufacturing

26th September 2025
Next Post

Strativa Pharmaceuticals Announces FDA Approval of Nascobal® (Cyanocobalamin, USP) Nasal Spray Single-Use Device

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In